Jeffrey Hung
Stock Analyst at Morgan Stanley
(3.36)
# 983
Out of 4,979 analysts
221
Total ratings
45.8%
Success rate
3.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Overweight | $158 → $163 | $144.17 | +13.06% | 29 | Sep 5, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $162 → $163 | $128.53 | +26.82% | 9 | Aug 28, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $76 → $71 | $58.42 | +21.53% | 13 | Aug 20, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Overweight | $35 → $28 | $6.83 | +309.96% | 7 | Aug 18, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Overweight | $20 → $21 | $12.52 | +67.80% | 4 | Aug 18, 2025 | |
| ERAS Erasca | Downgrades: Equal-Weight | $4 → $2 | $1.61 | +24.22% | 4 | Aug 18, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Equal-Weight | $17 → $13 | $7.12 | +82.58% | 6 | Aug 12, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $100 → $109 | $101.44 | +7.45% | 12 | Aug 6, 2025 | |
| FOLD Amicus Therapeutics | Upgrades: Overweight | $102 → $108 | $7.89 | +1,268.82% | 5 | Jul 17, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $65 → $55 | $31.50 | +74.60% | 9 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $52 → $56 | $33.42 | +67.59% | 4 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $24 | $24.84 | -3.38% | 25 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $34 | $5.55 | +512.61% | 3 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $60.34 | +40.87% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $20.85 | +29.50% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $5 | $4.99 | +0.20% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $70 → $67 | $51.50 | +30.10% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $10.00 | +250.00% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $70 | $36.50 | +91.78% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $1.20 | +233.33% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $1.22 | +227.87% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $7.05 | +98.58% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $3.32 | +50.60% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $2.54 | +18.11% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $1.73 | +709.25% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $2.26 | +342.48% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $38.28 | -42.53% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $14.48 | +925.55% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $1.55 | +3,770.97% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $4.01 | +49.81% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $5.13 | +12,531.58% | 6 | May 8, 2020 |
Neurocrine Biosciences
Sep 5, 2025
Maintains: Overweight
Price Target: $158 → $163
Current: $144.17
Upside: +13.06%
Jazz Pharmaceuticals
Aug 28, 2025
Maintains: Overweight
Price Target: $162 → $163
Current: $128.53
Upside: +26.82%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $76 → $71
Current: $58.42
Upside: +21.53%
Cullinan Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $35 → $28
Current: $6.83
Upside: +309.96%
Contineum Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $20 → $21
Current: $12.52
Upside: +67.80%
Erasca
Aug 18, 2025
Downgrades: Equal-Weight
Price Target: $4 → $2
Current: $1.61
Upside: +24.22%
Bicycle Therapeutics
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $17 → $13
Current: $7.12
Upside: +82.58%
Rhythm Pharmaceuticals
Aug 6, 2025
Maintains: Overweight
Price Target: $100 → $109
Current: $101.44
Upside: +7.45%
Amicus Therapeutics
Jul 17, 2025
Upgrades: Overweight
Price Target: $102 → $108
Current: $7.89
Upside: +1,268.82%
Ultragenyx Pharmaceutical
Jul 14, 2025
Maintains: Overweight
Price Target: $65 → $55
Current: $31.50
Upside: +74.60%
Jun 17, 2025
Maintains: Overweight
Price Target: $52 → $56
Current: $33.42
Upside: +67.59%
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $24.84
Upside: -3.38%
Mar 11, 2025
Maintains: Overweight
Price Target: $37 → $34
Current: $5.55
Upside: +512.61%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $60.34
Upside: +40.87%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $20.85
Upside: +29.50%
Mar 7, 2025
Assumes: Underweight
Price Target: $5
Current: $4.99
Upside: +0.20%
Feb 13, 2025
Upgrades: Overweight
Price Target: $70 → $67
Current: $51.50
Upside: +30.10%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $10.00
Upside: +250.00%
May 23, 2024
Maintains: Overweight
Price Target: $50 → $70
Current: $36.50
Upside: +91.78%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $1.20
Upside: +233.33%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $1.22
Upside: +227.87%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $7.05
Upside: +98.58%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $3.32
Upside: +50.60%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $2.54
Upside: +18.11%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $1.73
Upside: +709.25%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $2.26
Upside: +342.48%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $38.28
Upside: -42.53%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $14.48
Upside: +925.55%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $1.55
Upside: +3,770.97%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $4.01
Upside: +49.81%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $5.13
Upside: +12,531.58%